The first week of September had its share of winners and losers in the stock market. Commission free trading motivates one and all to start trading. But it is also important to keep tabs on how the market performs. Companies in the medical field led the growth.
Pharmaceutical company Endo International Plc ($ENDP) was a top gainer with a growth of 47.67% and a Buy rating on Trading View. Medical technology company Microbot Medical Inc ($MBOT) was rated a Strong Buy with 44.08% growth. Pier 1 Imports Inc ($PIR) was given a Buy rating after it experienced 25.71% growth. Ambow Education Holding Ltd ($AMBO) was categorized a Sell despite its 22.50% growth.
Among the stocks in the S&P 500, Symantec Corp ($SYMC) had a 4.47% rise to $24.52. Perrigo Company PLC ($PRGO) had a 3.65% rise to $49.92. Alexion Pharmaceuticals Inc ($ALXN) soared 3.55% to $103.84. Tapestry Inc grew 3.36% to $23.69.
Domo Inc ($DOMO) sank 37.45% for a Sell rating on Trading View. Avid Bioservices Inc ($CDMO) sank 22.98% to get a Sell rating. Merrimack Pharmaceuticals Inc ($MACK) was a Strong Sell after it sank 20.29%.
In the S&P 500, Advanced Micro Devices Inc ($AMD) had a 2.98% drop to $30.56. Monster Beverage Corp ($MNST) dropped 2.72% to $57.17. WEC Energy Corp Inc ($WEC) sank 2.31% to $93.31.
With advanced stock market trading software, you can always keep in touch with the markets and make informed decisions.
The content provided here is solely for informational and educational purposes and does not constitute an offer to sell or a solicitation to buy any security or instrument which may be referenced upon the site, or an offer to provide advisory or other services by TradeZero in any jurisdiction in which such offer, solicitation, purchase or sale would be unlawful under the securities laws of such jurisdiction. Investors are advised not to rely on the information contained in this writing to make an informed investment or financial decision. TradeZero explicitly disclaims all liability for any action taken based on any information contained in this writing.